Edition:
United States

Soleno Therapeutics Inc (SLNO.OQ)

SLNO.OQ on NASDAQ Stock Exchange Capital Market

1.72USD
21 Feb 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$1.72
Open
$1.71
Day's High
$1.71
Day's Low
$1.71
Volume
32
Avg. Vol
24,563
52-wk High
$4.15
52-wk Low
$1.35

Select another date:

Tue, Feb 20 2018

BRIEF-Soleno Therapeutics Announces Successful End-Of-Phase II Meeting With FDA For DCCR In Prader-Willi Syndrome

* SOLENO THERAPEUTICS ANNOUNCES SUCCESSFUL END-OF-PHASE II MEETING WITH FDA FOR DCCR IN PRADER-WILLI SYNDROME

BRIEF-Soleno Therapeutics Files For Resale Of Up To 14.2 Mln Shares

* SOLENO THERAPEUTICS INC FILES FOR RESALE OF UP TO 14.2 MILLION SHARES OF COMMON STOCK BY THE SELLING STOCKHOLDERS - SEC FILING Source text: (http://bit.ly/2DKTA0l) Further company coverage:

BRIEF-Jack W. Schuler Living Trust Reports 13.4 Pct Stake In Soleno Therapeutics As Of December 15

* JACK W. SCHULER LIVING TRUST REPORTS 13.4 PERCENT STAKE IN SOLENO THERAPEUTICS INC AS OF DECEMBER 15 - SEC FILING Source text: (http://bit.ly/2mkVVHQ) Further company coverage:

BRIEF-Soleno Therapeutics Says Board Resolved To Decrease Size Of Board From Ten To Seven

* SOLENO THERAPEUTICS SAYS ON JAN 2, BOARD RESOLVED TO DECREASE SIZE OF BOARD FROM TEN DIRECTORS TO SEVEN DIRECTORS - SEC FILING Source text for Eikon: (http://bit.ly/2F27EUa) Further company coverage:

BRIEF-Birchview Capital LP Reports A 6.17 Pct Passive Stake In Soleno Therapeutics

* BIRCHVIEW CAPITAL LP REPORTS A 6.17 PCT PASSIVE STAKE IN SOLENO THERAPEUTICS AS OF DEC 15 - SEC FILING Source text for Eikon: (http://bit.ly/2DT2Zn3) Further company coverage:

BRIEF-Soleno Therapeutics Announces $15 Million Private Placement

* SOLENO THERAPEUTICS ANNOUNCES $15 MILLION PRIVATE PLACEMENT

BRIEF-Soleno Therapeutics Announces Joint Venture Agreement For Commercialization Of Cosense Monitoring Technology

* SOLENO THERAPEUTICS ANNOUNCES JOINT VENTURE AGREEMENT FOR DEVELOPMENT AND COMMERCIALIZATION OF COSENSE MONITORING TECHNOLOGY

BRIEF-Soleno Therapeutics posts Q3 loss $0.24/shr from continuing operations

* Soleno Therapeutics provides corporate update and reports third quarter 2017 financial results

BRIEF-Soleno Therapeutics regains compliance with Nasdaq listing requirements

* Soleno Therapeutics regains compliance with nasdaq listing requirements Source text for Eikon: Further company coverage:

BRIEF-Soleno Therapeutics announces 1-for-5 reverse stock split

* Soleno Therapeutics - reverse stock split of all of co's outstanding common shares at an exchange ratio of 1-for-5 will take effect on October 6, 2017 Source text for Eikon: Further company coverage:

Select another date: